

AD _____

Award Number: DAMD17-99-1-9194

TITLE: Insulin Like Growth Factor I Receptor Function in Estrogen
Receptor Negative Breast Cancer

PRINCIPAL INVESTIGATOR: Michele Dougherty

CONTRACTING ORGANIZATION: Georgetown University Medical Center
Washington, DC 20057

REPORT DATE: July 2000

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20001020 033

DTIC QUALITY INSPECTED 4

REPORT DOCUMENTATION PAGE

OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE July 2000	3. REPORT TYPE AND DATES COVERED Annual Summary (1 Jul 99 - 30 Jun 00)	
4. TITLE AND SUBTITLE Insulin Like Growth Factor I Receptor Function in Estrogen Receptor Negative Breast Cancer			5. FUNDING NUMBERS DAMD17-99-1-9194	
6. AUTHOR(S) Michele Dougherty				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Georgetown University Medical Center Washington, DC 20057 E-MAIL: doughem2@gunet.georgetown.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) A recent CALGB 9344 trial (INT 048) examined the addition of paclitaxel therapy to standard chemotherapy regimes. The results of this trial demonstrated addition of paclitaxel to standard adjuvant therapy, doxorubicin and cyclophosphamide, was associated with proportional reductions in both relapse risk and risk of death. Subgroup analyses were conducted to identify tumor characteristics that would predict response to paclitaxel treatment. These analyses showed that the benefit of paclitaxel treatment was restricted to ER- patients (CALGB central statistics office), indicating that there was an association between estrogen receptor status and paclitaxel sensitivity. The results reported here demonstrate that the differences in growth between ER+ and ER- breast cancer cells reflect the differential sensitivity to paclitaxel observed both <i>in vitro</i> and in the clinic.				
14. SUBJECT TERMS Breast Cancer			15. NUMBER OF PAGES 14	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

N/A Where copyrighted material is quoted, permission has been obtained to use such material.

N/A Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

N/A Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

N/A In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

N/A For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Michele K. Dwyer

PI - Signature

8/14/00

Date

TABLE OF CONTENTS

Cover	1
SF 298	2
Foreword	3
Table of Contents	4
Introduction	5
Body	6-9
Conclusions	9
Revised Specific Aims and Statement of Work	10-11
References	12-14
Reportable Outcomes	15

INTRODUCTION

The project funded by this grant involved determining the function of the insulin like growth factor 1 (IGF1R) in estrogen receptor negative (ER-) breast cancer. While establishing an *in vitro* model of IGF1R+/ER- breast cancer, a second project was initiated examining the sensitivity of ER+ and ER- breast cancer to paclitaxel treatment. The interest in this particular question arose from the results of the recent CALGB 9344 trial (INT 048) that examined the addition of paclitaxel therapy to standard chemotherapy regimes. The results of this trial demonstrated addition of paclitaxel to standard adjuvant therapy, doxorubicin and cyclophosphamide, was associated with proportional reductions in both relapse risk and risk of death. Subgroup analyses were conducted to identify tumor characteristics that would predict response to paclitaxel treatment. These analyses showed that the benefit of paclitaxel treatment was restricted to ER- patients (CALGB central statistics office), indicating that there was an association between estrogen receptor status and paclitaxel sensitivity. The results reported here demonstrate that the differences in growth between ER+ and ER- breast cancer cells reflect the differential sensitivity to paclitaxel observed both *in vitro* and in the clinic.

BODY

Defining breast tumor characteristics that will aid in predicting response to treatment is an area of considerable interest when designing new therapeutic strategies. Clearly, the most valuable predictive marker currently available to clinicians is the presence or absence of ER. Estrogen receptor expression is predictive for response to hormone therapy in the majority of breast cancer patients (1). Predicting tumor response to cytotoxic chemotherapy has proven to be more difficult due to heterogeneity of breast cancer. Currently, the only cellular component that is predictive of response to certain types of chemotherapy is the ErbB 2 receptor (2,3). However, certain tumor characteristics have been identified that indicate whether a patient is more likely to respond to the effects of cytotoxic chemotherapy.

The kinetic characteristics of breast cancer have proven to be valuable for identifying patients with a better prognosis as well as helping to define a group of patients which may respond more favorably to chemotherapy treatment. Initial comparisons of the growth characteristics of ER+ and ER- breast cancer indicated that ER- cancers were associated with a increased proliferative rate as determined by thymidine labeling index and S-phase fraction (4,5). These observations have been extended in several analyses to demonstrate that increased proliferative rate is associated with a decreased time to relapse (6,7,8,9) and decreased overall survival rates in breast cancer patients (9). Increased proliferative rate is positively correlated





Figure 1. A) cells were plated in 1% or 5% FBS and counted using a Coulter counter at the indicated time points. Results are expressed as fold change in cell number. B) MCF-7 cells were plated in 10% FBS and C4-12 cells were plated in 10% CCS. Cells were quantified as in A.

with increased survival following chemotherapy (4,10). A large retrospective analysis also indicated that there is increased benefit of chemotherapy treatment for women with ER negative breast cancer, particularly among post-menopausal women (11).

Since many chemotherapeutic agents exert cell cycle specific effects, tumors with higher proliferative rates are likely to be more susceptible to the effects of these drugs. Paclitaxel in particular is a cell cycle specific drug as it stabilizes microtubules, causing cells to be blocked in mitosis and subsequently undergo apoptosis (12,13,14).

The results reported for the CALGB 9344

trial indicate that ER- tumors are more susceptible to the effects of paclitaxel treatment. Since the effects of paclitaxel are cell cycle specific, we hypothesized that ER negative breast cancers

are more susceptible to the cytotoxic effects of paclitaxel due to an increase in proliferation of these tumors, resulting in the increased survival rates observed for ER- patients treated with paclitaxel.

Two *in vitro* models of ER- breast cancer were used to evaluate the sensitivity of ER+




Figure 2a




Figure 2b

Figure 2. A) A18 cells were plated in 1% or 5% FBS, paclitaxel treatment was initiated 24 hours later. Cell viability was assessed at 48 hours with the Wst-1 assay. Percentage of viable cells following treatment was calculated from triplicate wells. B) 2W cells were plated in 1% or 5% FBS and treated as in A.

respectively.

Growth assays were utilized to determine differences in growth between the ER positive T47D:A18 (A18) and ER negative T47D:C4:2W (2W) cells and ER+ MCF7 cells and ER- ECMCF-7 C4-12 (C4-12) cells. The results of these assays demonstrate that there were significant differences in growth between A18 and 2W cells in both low (1% FBS) and high (5% FBS) serum conditions (Fig 1a). Additionally, A18 cells have a decreased doubling time in low serum conditions (96 hours) compared to high serum conditions (48 hours) indicating that a dependence on serum associated growth factors such as estrogen. This model demonstrates that *in vitro* ER- cells have a significantly higher growth rate than ER+ cells. ER negative C4-12 cells have an increased doubling time when compared to parental MCF-7 cells, while this model

and ER- cells to paclitaxel. An ER positive T47D cell line, T47D:A18 (A18), and an ER negative clone, T47D:C4:2 W (2W) generated by limited dilution cloning in the absence of estrogen provided one model of ER- breast cancer cell growth (15). MCF-7 cells and an ER- clone generated in a similar manner provided a second model (Gift of Dr. W. Welshons and Dr. E. Curran, Univ. of Missouri). Proliferation was evaluated by quantifying cell number over time. Cell viability and apoptosis following paclitaxel treatment at low and high serum concentrations was assessed using the Wst-1 assay and Cell Death ELISA,

does not demonstrate the increased proliferation characteristic of ER- cell lines, it is a useful model to examine the correlation between growth and paclitaxel sensitivity in breast cancer (Fig 1b).




Figure 3. MCF-7 cells were treated in 10% FBS and C4-12 in 10% CCS with paclitaxel for 48 hours. Cell viability was determined with the Wst-1 assay. Results are expressed as percentage of viable cells following taxol treatment.


Cell viability and apoptosis were assessed following paclitaxel treatment. Cell viability was determined with the Wst-1 assay, a reagent that is metabolized by intact mitochondria and quantified photometrically and is directly proportional to cell

number. The results of these experiments demonstrate that ER positive A18 cells are sensitive to a range of paclitaxel concentrations in 5% FBS ,

but are less sensitive when treated in 1% FBS, a condition where the cells have are proliferating more slowly (Fig 2a and 1a). However, ER negative 2W cells grow equally well in low and high serum conditions and display a similar level of sensitivity to paclitaxel in both 1% and 5% FBS (Fig 2b and 1a). Similarly, parental MCF-7 cells are more sensitive to paclitaxel than are C4-12 cells, which have decreased growth when compared to MCF-7 cells (Fig 3 and 1b). These results suggest breast cancer cells with slower proliferative rates are less sensitive to the cytotoxic effects of paclitaxel than are cells with a rapid proliferative rate.

The Wst-1 assay quantifies viable cells, to measure cell death induced by paclitaxel, apoptosis was evaluated with a Cell Death ELISA (Roche). Histone bound DNA cleaved during apoptosis is detected in cellular lysates with a primary antibody against histone and a secondary antibody against DNA conjugated to a reporter enzyme. Processing of added substrate allows photometric quantification of apoptosis. Apoptosis induced by paclitaxel treatment was greater in A18 cells treated in high serum compared to the level of apoptosis induced in low serum conditions. Paclitaxel treatment of 2W cells induces high levels of apoptosis in both low and high serum conditions. Collectively these data indicate that in this model the paclitaxel

sensitivity of these breast cancer cell lines is related to proliferation. MCF-7 and C4-12 cells will also be evaluated for induction of apoptosis using the cell death ELISA. Additionally, an ER- clone (LCC3) of the ER+ ZR-75-1 cell line has recently been obtained (gift of Dr. R. Clarke,



Lombardi Cancer Center, Georgetown University). The ZR-75-1 parental ER+ cell line and the ER- clone, LCC3, will be evaluated for growth and paclitaxel sensitivity to confirm the results presented here.

Figure 4. Apoptosis was determined by quantifying the amount of histone-bound DNA in cytoplasmic extracts of A18 and 2W following 48 hour exposure to 100nM paclitaxel or vehicle control in 1% and 5% FBS. .

CONCLUSIONS

The conclusion drawn from this data identifies an important factor impacting paclitaxel sensitivity in breast cancer. In this model, the effect of estrogen receptor expression on paclitaxel sensitivity is related to the growth regulatory properties of ER. ER negative 2W cells have achieved estrogen independence, allowing for increased proliferation. While these cells can survive in poor growth conditions (1% FBS), this adaptation has rendered the cells more susceptible to the effects of paclitaxel, a cell cycle specific drug. The breast cancer cell lines utilized in this project provide important models for studies detailing progression to estrogen independence in breast cancer. The remainder of this project will focus on evaluating the changes in growth factor signaling pathways and cell cycle components that allow these cells to achieve estrogen independence.

Revised Specific Aims and Statement of Work

Progression of breast cancer from an estrogen-dependent, ER positive status to an estrogen-independent, ER negative status is the focus of much current research. Observations made both from *in vitro* models and clinical research indicates that upregulation of growth factor signaling pathways is correlated with progression to estrogen independence and loss of estrogen receptor expression. Increased levels of MEK and Raf-1 as well as increased expression and activity of MAP kinase has been observed in breast cancer, indicating that hyperactivation of growth signaling pathways is an important factor in breast cancer progression (16,17). Additionally, increased expression of both the erbB2 and EGF receptors is observed in ER- breast cancer (18, 19, 20,21). *In vitro* models where these growth factor receptors have been over-expressed in the ER+ MCF-7 cell line suggest that increased signaling through growth factor receptors is an important step in the progression to estrogen independence (22,23). More recently, increased MAP kinase activity has been shown to contribute to both estrogen-independent growth and the loss of ER- expression *in vitro* (24,25).

The T47D:A18, MCF-7 and ZR-75-1 cell lines along with their ER negative counterparts, all derived by selecting for cell growth in the absence of estrogen, provide models for further examining the status of growth factor signaling pathways in ER- breast cancer. Preliminary data suggests that the ER- 2W, LCC3 and C4-12 cell lines have decreased MAP kinase activity compared to the parental ER + cell lines but maintain MAP kinase expression at levels similar to the parental cell lines (data not shown). This observation indicates these cells may not be dependent on the MAP kinase pathway for growth. Further evaluation of these cell lines using western blot analysis has revealed that both A18 and 2W cells have increased levels of p70/S6 kinase activity (data not shown). p70/S6 kinase is a component of the PI-3-kinase pathway and is activated by ser/thr phosphorylation (26, 27). Both Akt and phosphatidyl inositide dependent kinase I (PDKI) have been shown to mediate activation of p70/S6 kinase (27, 28). Activation of p70/S6 kinase facilitates phosphorylation of the ribosomal S6 subunit and subsequently protein

synthesis (29 30). p70/S6 kinase is primarily activated during the G0/G1 and G1/S phase transition, suggesting a role in cell cycle progression (31). Additionally, a recent analysis has demonstrated gene amplification in 59% of breast tumors examined and this amplification was associated with a poorer prognosis (32). While no correlation with ER status was observed, this observation suggests that S6 kinase may play an important role in breast cancer progression (32). Expression and activity of S6 kinase in breast cancer contributes to breast cancer progression and represents an alternative growth pathway by which breast cancer cells can achieve estrogen independence.

SPECIFIC AIMS

1. Evaluate expression and activity of p70/S6 kinase in *in vitro* models of breast cancer
A) Utilize phosphorylation-site specific western blotting and p70/S6 kinase activity assays to determine the activity of p70/S6 kinase in the T47D, ZR-75-1 and MCF-7 cell lines and ER- counterparts
2. Evaluate the dependence of ER+ and ER- breast cancer on p70/S6 kinase activity by inhibit activity using pharmacologic inhibitors of S6 kinase activity and expression of dominant-negative p70/S6 kinase constructs and determine the impact on growth and estrogen receptor expression.
A) Evaluate the effect of rapamycin, a pharmacologic inhibitor of p70 S6/kinase activity, on growth of ER+ and ER- breast cancer cells *in vitro* and expression of the estrogen receptor.
B) Express a dominant-negative p70/S6 kinase construct in ER- breast cancer cells and assess growth and estrogen receptor status.

STATEMENT OF WORK

Task 1

Aim 1 (Months 12-18) Evaluate expression and activity of p70/S6 kinase in T47D, Zr-75 and MCF-7 ER+ and ER- breast cancer cells

Task 2

Aim 2A (Months 18-24) Perform growth assays to determine the effect of rapamycin treatment on growth of ER+ and ER- breast cancer cells in culture. Perform immunohistochemistry to determine the effect of rapamycin treatment on the expression of ER in ER+ and ER- breast cancer cells.

Aim 2B (Months 18-36) Stably express a dominant negative p70/S6 kinase in ER- breast cancer cell lines, confirm activity of dominant negative p70/S6 kinase and evaluate growth and ER status of stable transfected cell lines.

REFERENCES

1. McGuire, W.L., 1975. Current status of estrogen receptors in human breast cancer. *Cancer*. 36:638-644.
2. Paik, S., *et. al.* 1998. ErbB-2 and response to doxorubicin in patients with axillary lymph node positive, hormone receptor negative breast cancer. *J. Natl. Cancer Inst.* 90:1361-1370.
3. Thor, D.A., *et. al.* 1998. erB-2, p53 and efficacy of adjuvant therapy in lymph node positive breast cancer. *J. Natl. Cancer Inst.* 90:1346-1360.
4. Meyer, J.S., Rao, B.R., Stevens, S.C., White, W. L. 1977. Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular proliferation. *Cancer*. 40:2290-2298.
5. Wenger, C.R., Beardslee, S., Owens, M.A., Pounds, G., Oldaker, T., Vvendely, P., Pandian, M.R., Harrington, D., Clark, G.M., McGuire, W.L. 1993. DNA ploidy, S-phase and steroid receptors in more than 127,000 breast cancer patients. *Breast Cancer Research and Treatment*. 28:9-20.
6. Meyer, J.S., Hixon, B. 1979. Advanced stage and early relapse of breast carcinomas associated with high thymidine labeling indices. *Cancer Research*. 39:4042-4047.
7. Meyer, J.S., Lee, J.Y., 1980. Relationships of S-phase fraction of breast carcinoma in relapse to duration of remission, estrogen receptor content, therapeutic responsiveness and duration of survival. *Cancer Research*. 40:1890-1896.
8. Gentili, C., Sanfilippo, O., Silvestrini, R. 1981. Cell proliferation and its relationship to clinical features and relapse in breast cancer. *Cancer*. 48:974-949.
9. Silvestrini, R., Daidone, M.A., Gasparini, G. 1982. Cell kinetics as a prognostic marker in node-negative breast cancer. *Cancer*. 56:1982-1987.
10. Sulkes, A., Livingston, R.B, Murphy, W.K. 1979. Tritiated thymidine labeling index and response in human breast cancer. *J. Natl Cancer Inst.* 62:513-515.
11. Early Breast Cancer Trialists Collaborative Group. 1998. Polychemotherapy for early breast cancer: an overview of the randomised trials. *Lancet*. 352:930-942.
12. Jordan, M.A., Toso, R.J, Thrower, D., Wilson, L. 1993. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. *Proc. Natl. Acad. Sci.* 90:9552-9556.
13. Torres, K., Horwitz, S.B. 1998. Mechanisms of taxol-induced death are concentration dependent. *Cancer Research*. 58:3620-2626.
14. Trielli, M.O., Andreassen, P.R., Lacroix, F.B., Margolis, R.L. 1996. Differential taxol-dependent arrest of transformed and nontransformed cells in G1 phase of the cell cycle and specific-related mortality of transformed cells. *J. Cell Biology*. 135:689-700.

15. Pink, J.J., Bilimoria, M.M., Jordan, V.C. 1996. Irreversible loss of the estrogen receptor in T47D breast cancer cells following prolonged estrogen deprivation. *British Journal of Cancer*. 74:1227-1236.
16. Sivaraman, V.S., Wang, H., Nuovo, G.J., Malbon, C.C. 1997. Hyperexpression of mitogen-activated protein kinase in human breast cancer [see comments]. *J. Clin. Invest.* 99:1478-1483.
17. Salh, B., Marotta, A., Matthewson, C., Flin, J., Owen, D., Pelech, S. 1999. Investigation of the Mek-MAP kinase-Rsk pathway in human breast cancer. *Anticancer Res.* 19:731-740.
18. Sainsbury, J.R., Farndon, J.R., Sherbet, G.V., Harris, A.L. 1985. Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. *Lancet*. 1:364-366.
19. Gusterson, B.A. 1992. Identification and interpretation of epidermal growth factor and c-erbB-2 overexpression. *Eur. J. Cancer*. 28:263-267.
20. Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., McGuire, W.L. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science*. 235:177-182.
21. Perren, T.J. 1991. c-erbB-2 oncongene as a prognostic marker in breast cancer [editorial]. *Br. J. Cancer*. 46:2511-2519.
22. Liu, Y., El-Ashry, D., Chen, D., Ding, I.Y.F., Dern, F.G. 1995. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen sensitivity in vivo. *Breast Cancer Research and Treatment*. 34:97-117.
23. Miller, D.L., El-Ashry, D., Cheville, A.L., Liu, Y., McLeskey, S.W., Kern, F.G. 1994. Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor under estrogen depeleted conditions: evidence for a role of EGFR in breast cancer growth and progression. 5:1263-1274.
24. El-Ashry, D., Miller, D.L., Dharbanda, S., Lippman, M.E., Kern F.G. 1997. Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis. *Oncogene*. 15:423-435.
25. Oh, A.S., Lorant, L.A., Miller, D.M., Yarden R.I., Kern, F.G., El-Ashry, D. 2000. Hyperactivation of MAPK induces loss of ER expression in Breast Cancer. Submitted: *Molecular Endocrinology*.
26. Weng, Q-P., Andrabi, K., Kozlowski, M.T., Grove, J.R., Avruch, J. 1995. Multiple independent inputs are required for activation of the p70/S6 kinase. *Mol. Cell Biol.* 15(5):2333-2340.
27. Romanelli, A., Martin, K.A., Toker, A., Blenis, J. 1999. P70 S6 kinase is regulated by protein kinase C zeta and participates in phosphoinositide 3-kinase-regulated signaling complex. *Mol. Cell. Biol.* 19(4):2921-2928.

29. Kawasome, H., Papst, P., Webb, S., Keller, G.M., Johnson, G.L., Gelfand, E.W., Terada, N. 1998. Targeted disruption of p70/S6k defines its role in protein synthesis and rapamycin sensitivity. *Proc. Natl. Acad. Sci.* 95:5033-5038.
30. Jeffries H.B.J., Fumagalli, S., Dennis, P.B., Reinhard, C., Pearson, R.B., Thomas, G. 1997. Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70/S6K. *EMBO J.* 12:393-3704.
31. Terada, N., Franklin, R.A., Lucas, J.J., Blenis, J., Gelfand, E.W. 1993. Failure of rapamycin to block proliferation once resting cells have entered the cell cycle despite inactivation of p70 S6 kinase. *J. Biol. Chem.* 268(16):12062-12068.
32. Barlund, M., *et. al.* 2000. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis.